These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19458179)

  • 1. Development of a disk diffusion method for testing Moraxella catarrhalis susceptibility using clinical and laboratory standards institute methods: a SENTRY antimicrobial surveillance program report.
    Bell JM; Turnidge JD; Jones RN
    J Clin Microbiol; 2009 Jul; 47(7):2187-93. PubMed ID: 19458179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae.
    Jones RN; Biedenbach DJ; Erwin ME; Beach ML; Pfaller MA
    J Clin Microbiol; 1999 Jun; 37(6):1999-2002. PubMed ID: 10325362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disk diffusion versus broth microdilution susceptibility testing of Haemophilus species and Moraxella catarrhalis using seven oral antimicrobial agents: application of updated susceptibility guidelines of the National Committee for Clinical Laboratory Standards.
    Kibsey PC; Rennie RP; Rushton JE
    J Clin Microbiol; 1994 Nov; 32(11):2786-90. PubMed ID: 7852573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β-Lactamase production and antibiotic susceptibility pattern of Moraxella catarrhalis isolates collected from two county hospitals in China.
    Shi W; Wen D; Chen C; Yuan L; Gao W; Tang P; Cheng X; Yao K
    BMC Microbiol; 2018 Jul; 18(1):77. PubMed ID: 30029595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disk diffusion susceptibility testing of Branhamella catarrhalis with ampicillin and seven other antimicrobial agents.
    Doern GV; Tubert T
    Antimicrob Agents Chemother; 1987 Oct; 31(10):1519-23. PubMed ID: 3124732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contemporary prevalence of BRO beta-lactamases in Moraxella catarrhalis: report from the SENTRY antimicrobial surveillance program (North America, 1997 to 2004).
    Deshpande LM; Sader HS; Fritsche TR; Jones RN
    J Clin Microbiol; 2006 Oct; 44(10):3775-7. PubMed ID: 17021108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. bro {beta}-lactamase and antibiotic resistances in a global cross-sectional study of Moraxella catarrhalis from children and adults.
    Khan MA; Northwood JB; Levy F; Verhaegh SJ; Farrell DJ; Van Belkum A; Hays JP
    J Antimicrob Chemother; 2010 Jan; 65(1):91-7. PubMed ID: 19889789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of susceptibility patterns and BRO beta-lactamase types among clinical isolates of Moraxella catarrhalis.
    Esel D; Ay-Altintop Y; Yagmur G; Gokahmetoglu S; Sumerkan B
    Clin Microbiol Infect; 2007 Oct; 13(10):1023-5. PubMed ID: 17608812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial susceptibility and impact of macrolide antibiotics on Moraxella catarrhalis in the upper and lower airways of children with chronic endobronchial suppuration.
    Hare KM; Seib KL; Chang AB; Harris TM; Spargo JC; Smith-Vaughan HC
    J Med Microbiol; 2019 Aug; 68(8):1140-1147. PubMed ID: 31274402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial resistance of Moraxella catarrhalis isolates in Taiwan.
    Hsu SF; Lin YT; Chen TL; Siu LK; Hsueh PR; Huang ST; Fung CP
    J Microbiol Immunol Infect; 2012 Apr; 45(2):134-40. PubMed ID: 22154675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of restriction endonuclease analysis of BRO beta-lactamases in clinical and carrier isolates of Moraxella catarrhalis.
    Köseoglu O; Ergin A; Hascelik G
    Scand J Infect Dis; 2004; 36(6-7):431-4. PubMed ID: 15307563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multilaboratory evaluation of disk diffusion antimicrobial susceptibility testing of Neisseria meningitidis isolates.
    Jorgensen JH; Crawford SA; Fulcher LC; Glennen A; Harrington SM; Swenson J; Lynfield R; Murray PR; Tenover FC
    J Clin Microbiol; 2006 May; 44(5):1744-54. PubMed ID: 16672402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production of BRO beta-lactamases and resistance to complement in European Moraxella catarrhalis isolates.
    Schmitz FJ; Beeck A; Perdikouli M; Boos M; Mayer S; Scheuring S; Köhrer K; Verhoef J; Fluit AC
    J Clin Microbiol; 2002 Apr; 40(4):1546-8. PubMed ID: 11923393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moraxella catarrhalis uses a twin-arginine translocation system to secrete the β-lactamase BRO-2.
    Balder R; Shaffer TL; Lafontaine ER
    BMC Microbiol; 2013 Jun; 13():140. PubMed ID: 23782650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevalence of Moraxella catarrhalis in the nasopharyngeal specimen from 1 082 hospitalized children with respiratory infection and the drug resistance of the isolates].
    Tang P; Shi W; Zeng HL; Ding W; Wang C; Yao KH; Wen DN
    Zhongguo Dang Dai Er Ke Za Zhi; 2016 Aug; 18(8):707-12. PubMed ID: 27530786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molecular characterization of BRO beta-lactamases of Moraxella catarrhalis strains isolated from carrier children].
    Köseoğlu O; Ergin A; Gürkan Aydin N; Hasçelik G
    Mikrobiyol Bul; 2004 Oct; 38(4):335-40. PubMed ID: 15700658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The frequency of BRO β-lactamase and its relationship to antimicrobial susceptibility and serum resistance in Moraxella catarrhalis.
    Saito R; Nonaka S; Fujinami Y; Matsuoka S; Nakajima S; Nishiyama H; Okamura N
    J Infect Chemother; 2014 Jan; 20(1):6-8. PubMed ID: 24462416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study.
    Doern GV; Brueggemann AB; Pierce G; Hogan T; Holley HP; Rauch A
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2884-6. PubMed ID: 9124860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and molecular analysis of macrolide-resistant Moraxella catarrhalis clinical isolates in Japan, following emergence of the highly macrolide-resistant strain NSH1 in 2011.
    Kasai A; Ogihara S; Yamada K; Tanimichi Y; Nishiyama H; Saito R
    J Med Microbiol; 2015 Jul; 64(7):708-713. PubMed ID: 25934551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY antimicrobial Surveillance Program (United States and Canada, 1997).
    Doern GV; Jones RN; Pfaller MA; Kugler K
    Antimicrob Agents Chemother; 1999 Feb; 43(2):385-9. PubMed ID: 9925540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.